Ocular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.38), $0.01 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $14.54 million versus the consensus estimate of $14.63 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.